PDCD1 and melanoma: In line with our observation of latent and enhanced responsiveness, proliferation marker Ki67 was highly expressed in PD-1+CD8+ T cells in another melanoma study after three weeks of treatment with the anti-PD1-inhibitor, an analysis performed with PMBC of 29 stage IV melanoma patients [11].